GlassScriptPhysician profile
Mark T Kimpton
NPI 1124094669
$3,967.17
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,471 · 2020: $1,041 · 2021: $1,455.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $680.11 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $679.36 | 2019-2021 | |
| Amgen INC. | $433.19 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $246.50 | 2019-2021 | |
| Glaxosmithkline, LLC. | $222.09 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $181.38 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $156.46 | 2019-2021 | |
| Hikma Pharmaceuticals USA | $151.39 | 2020-2021 | |
| Lilly USA, LLC | $131.51 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $125.65 | 2019-2021 | |
| Abbvie INC. | $110.52 | 2019-2021 | |
| Pfizer INC. | $101.87 | 2019-2021 | |
| Esperion Therapeutics, INC. | $100.65 | 2020-2021 | |
| Grifols USA, LLC | $93.94 | 2020-2021 | |
| Allergan, INC. | $76.37 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $74.69 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $72.59 | 2019-2021 | |
| Ultragenyx Pharmaceutical INC. | $55.83 | 2019-2021 | |
| Amarin Pharma, INC. | $53.46 | 2020-2021 | |
| Eisai INC. | $42.76 | 2020-2021 | |
| Paratek Pharmaceuticals, INC. | $24.64 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $24.41 | 2019 | |
| Redhill Biopharma INC. | $21.47 | 2021 | |
| Daiichi Sankyo INC. | $20.56 | 2021 | |
| Radius Health, INC. | $18.34 | 2019 | |
| Sanofi Pasteur INC. | $16.86 | 2019 | |
| Abbott Laboratories | $14.41 | 2021 | |
| Novartis Pharmaceuticals Corporation | $12.36 | 2021 | |
| Boston Scientific Corporation | $12.30 | 2019 | |
| Ironwood Pharmaceuticals, INC | $11.50 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Kimpton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.